Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/7/22 Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022 9/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy 9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027 9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027 9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023 9/7/22 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year 9/6/22 Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 9/6/22 Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy 8/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 41 - 50 of 788 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/7/22 Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022 9/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy 9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027 9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027 9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023 9/7/22 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year 9/6/22 Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference 9/6/22 Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy 8/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 41 - 50 of 788